All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

HER2 Status in Low-grade Serous Ovarian Tumors

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F25%3A00079951" target="_blank" >RIV/00209805:_____/25:00079951 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/25:10484144 RIV/00216208:11120/25:43927516 RIV/00216208:11130/25:10484144 RIV/00216208:11150/25:10484144 and 4 more

  • Result on the web

    <a href="https://journals.lww.com/intjgynpathology/abstract/2025/07000/her2_status_in_low_grade_serous_ovarian_tumors.5.aspx" target="_blank" >https://journals.lww.com/intjgynpathology/abstract/2025/07000/her2_status_in_low_grade_serous_ovarian_tumors.5.aspx</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1097/PGP.0000000000001059" target="_blank" >10.1097/PGP.0000000000001059</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    HER2 Status in Low-grade Serous Ovarian Tumors

  • Original language description

    Using immunohistochemistry, we examined a large cohort of 135 ovarian tumors, made up of 96 low-grade serous carcinomas (LGSCs) and 39 serous borderline tumors (micropapillary variant, mSBT), with the aim of exploring their HER2 status (overexpression). We followed with comprehensive genomic analyses on this sample set from our previous study, which revealed HER2 mutation in 5% (4/75) of LGSC and 10% (3/29) of mSBT. No cases were evaluated as HER2-positive, but 6 LGSCs and 1 mSBT were scored as HER2 1+, and 2 LGSCs and 1 mSBT showed the so-called HER2 &quot;ultra-low&quot; phenotype. This could be of clinical value as a potential therapeutical target concerning emerging therapeutic treatments (antibody conjugates). However, the clinical significance of this expression still needs to be established.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2025

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    International journal of gynecological pathology

  • ISSN

    0277-1691

  • e-ISSN

    1538-7151

  • Volume of the periodical

    44

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    5

  • Pages from-to

    331-335

  • UT code for WoS article

    001508074300010

  • EID of the result in the Scopus database

    2-s2.0-85203239195